News

The movie joined 2025 Netflix releases earlier this year, but after it made the top of NY Times ’ greatest films of the 21st ...
David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...
Scholar Rock shares launched 362% to 34.28. That put shares at their highest point since November 2021. The news also buoyed shares of Biohaven, which is working on a similar treatment option for ...
Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate ...
Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.
Scholar Rock's lead candidate, apitegromab, showed promising Phase 3 results in SMA, boosting shares by over 325%, with plans for regulatory submissions in the US and EU. Despite positive data ...
Scholar Rock Holding Corp.'s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late-stage trial of a ...
Scholar Rock, a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein ...
CAMBRIDGE, Mass., February 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...
Scholar Rock said on Wednesday a combination of its experimental drug and Eli Lilly's weight-loss treatment Zepbound helped overweight patients preserve significantly more lean mass in a mid-stage ...
Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.